Abstract
Adult genetic disorders causing brain lesions have been mostly described as white matter vanishing diseases. We present here the investigations realized in patients referred for psychiatric disorder with magnetic resonance imaging showing atypical basal ganglia lesions. Genetic explorations of this family revealed a new hereditary disease linked to glutathione metabolism.
Introduction
Brain cavitations are observed in conditions such as stroke, multiple sclerosis, infectious, or genetic diseases.1, 2, 3, 4 For most of the inherited diseases, early presentations are linked to mitochondrial defect, and in adults, these lesions have been essentially described in vanishing white matter diseases.4, 5, 6, 7, 8 Following investigations in a family referred to our center for psychiatric and/or neurologic disorders, we describe here a specific combination of cystic lesions in basal ganglia with a metabolic profile resulting in a positive sulfite urine test. Genetic and metabolic explorations suggest a new hereditary syndrome due to a loss of function in the NIT1 gene impairing glutathione metabolism.
Clinical Reports
The index case (II.4 Table 1 and Fig. 1A), a 34 years old man, was admitted in the emergency ward for a sudden left hemiparesis. He had a history of a nonsevere mental retardation, and was admitted 2 years before in psychiatry unit for an acute psychotic episode followed by generalized seizures. Upon clinical examination, a pure motor left hemiparesis was diagnosed and a stroke was suspected. A computed tomography scan (CT scan) and a magnetic resonance imaging (MRI) T1 and T2 (0.5 T) showed bilateral small cystic lesions affecting basal ganglia. Arteriography was normal as well as electroencephalography (EEG), electromyography (EMG), Doppler ultrasound, and cardiac echocardiography. Among biological analysis, a dipstick urine test for sulfites (MQuant, VWR®) was positive. The clinical status of the patient progressively worsened over a 20 years period with a severe neuropsychological deterioration and a spastic tetraplegia. He died in 2011, no autopsy was performed. In 2014, one of his brother (II.5, Table 1 and Fig. 1A) was admitted in the intensive care for a sudden coma with cardiovascular collapse. He was a 58 years old man with a history of diabetes mellitus and had lived an active professional life. The CT and the MRI (3 T) showed the same abnormalities as the patient II.4 (Fig. 2) and CT. The urine sulfite test was also positive. The patient progressively recovered but presented with a neuropsychological deterioration (BREF: 14/18, MMSE: 22/30).
Table 1.
Clinical, biochemical, and genetic findings in family members.
| Current age/age of death | Clinical phenotype | Brain MRI defects | Urine sulfite dipstick test | Genetic status for NIT1 | |
|---|---|---|---|---|---|
| I.1 | Age of death: 77 | N.R. | N.A. | N.A. | N.A. |
| I.2 | 84 | N.R. | N.A. | − | c.457G> A +/− |
| c.670dupA −/− | |||||
| II.1 | 69 | N.R. | N.A. | N.A. | N.A. |
| II.2 | 67 | N.R. | N.A. | N.A. | N.A. |
| II.3 | 66 | N.R. | N.A. | − | c.457G> A −/− |
| c.670dupA −/− | |||||
| II.4 | Age of death: 57 | Mental retardation, Psychotic episodes, Seizures | Basal ganglia cystic lesions | + | N.A. |
| II.5 | 63 | Sudden coma with cardiovascular collapse, Neuropsychological deterioration | Basal ganglia cystic lesions | + | c.457G> A +/− |
| c.670dupA +/− | |||||
| II.6 | 61 | N.R. | N.A. | − | c.457G > A −/− |
| c.670dupA −/− | |||||
| II.7 | 60 | Schizophrenia | Basal ganglia cystic lesions | + | c.457G > A +/− |
| c.670dupA +/− | |||||
| II.8 | 58 | N.R. | N.A. | − | c.457G > A −/− |
| c.670dupA −/− | |||||
| II.9 | Age of death: 17 | Suicide | N.A. | N.A. | N.A. |
N.R., not reported yet; N.A, not available or tested; − tested negative, + tested positive.
Figure 1.

(A) Pedigree of the family. (B and C) Sequencing for the c.457G > A and c.670dupA variants upper part shows a control sequence (C) and the lower part shows the sequence from patient II.5 (P). (D) NIT1 protein detection. Proteins were extracted from skin cutaneous control (C) or patient II.5 (P) fibroblasts and separated on SDS‐PAGE. Anti‐Nit1 antibody (Abcam®) or anti‐Tubulin antibody (loading control) was used for the western blot. (E) GC/MS detection of a dGSH derivative in the urine of patient II.4 as described.9, 10 The compound only present in the patient urine is marked by an arrow on the chromatogram (upper part) with retention time of 34.45 min. It was identified as dGSH by mass spectrometry (lower part) by the presence of two specific peaks (circle). The mass spectrum of the compound is similar to the one present in the urine of Nit1‐Knock Out mice and corresponds to a dGSH derivative (m/z 398 for the apparent molecular ion, m/z 383 for M‐15, and m/z 355) as previously described9. The same peaks were observed in urine of his brothers (II.5 and II.7) but were undetectable in the other siblings tested and the mother.
Figure 2.

Brain MRI of the patient II.5. Axial T2‐weighted image showing deep cavitating state (3 T).
Due to a recurrent phenotype, a familial investigation was undertook. A third brother of the family was in a psychiatric institution for a schizophrenia diagnosed 40 years ago (II.7). His clinical examination was normal, but the CT scan and the MRI (3 T) found the same brain lesions together with a positive urine sulfite test. The mother (I.2) and three others brothers and sisters (II.3, II.6, II.7), had no symptoms nor positive sulfite test in urine samples.
An inherited recessive disorder was suspected and an exome study was performed on individuals II.7 and II.5 DNA. After excluding “OMIM” diseases with a special attention on genes involved in cavitation encephalopathy and sulfite metabolism, two rare variants were found in the NIT1 gene (Nitrilase‐like protein 1, NM_005600): an heterozygous c.457G > A;p.Gly153Arg variation and an heterozygous c.670dupA;p.Thr224Asnfs*41 variation (Fig. 1B–C). The familial study showed that asymptomatic brothers and sisters, whose DNA was available, had neither of the variants, and that the c.670dupA was inherited from the asymptomatic mother. The father's DNA was not available, but molecular cloning of a PCR fragment encompassing both variations from patient II.5 showed that they were initially present on different alleles of the gene (not shown).
The c.670dupA variant is predicted to induce a loss of function of the NIT1 allele due to a frameshift in the coding sequence. The c.457G > A variant induces the replacement of a highly conserved Glycine to an Arginine. It is also located on the last nucleotide of exon 4 and predicted to affect the splicing of NIT1 mRNA, which was next demonstrated by sequencing of the NIT1 transcript extracted from a skin biopsy of patient II.5 (data not shown). Overall, the combination of the two variations should lead to a loss of expression of the NIT1 gene. Accordingly, the level of Nit1 protein was undetectable by western blot in fibroblasts from patient II.5 (Fig. 1D).
The NIT1 gene encodes a highly conserved enzyme whose amidase function is required to catalyze the recycling of deaminated glutathione (dGSH), a side product of several metabolic reactions, into 2‐ketoglutarate and cysteinylglycine leading to glutathione.9 Interestingly, the knock‐out of the gene in mice is responsible for the accumulation of dGSH that is excreted in urine.9 A qualitative organic acid analysis profile10 on urine samples of members of the family identified in individuals mutated for NIT1 an unusual compound with a mass spectrum identical to dGSH (Fig. 1E). Due to the link between oxidative stress and the NIT1 pathway, the activity of superoxide dismutase (SOD) as markers of cellular overproduction of free radicals was tested on fibroblasts of the patient. The cytoplasmic SOD (Cu/Zn SOD) activity was not changed, whilst the activity of the mitochondrial SOD (MnSOD) showed a twofold increase as compared to control samples (relative amount of SOD activity 2.0, SEM ± 0.1513 P = 0.0027 student t test).
Altogether, our study shows in symptomatic patients of the family loss of function mutations in the NIT1 gene, which probably induce an accumulation of dGSH in their organism as well as oxidative stress at the cellular level.
Discussion
We describe here the phenotype and genetic analysis of three brothers with a history of neuropsychological deterioration. All share specific brain damage identified by MRI and a positive urine sulfite test. The cavities detected by MRI in symptomatic members of the family are different from cavitary lesions frequently reported in adults,4, 11 especially because they locate in the basal ganglia. They may correspond to the so‐called “cerebral porosis” in historical classification of lacunar lesions of the brain.1 To date, the only known pathologies showing brain damage together with a positive urinary sulfite test are sulfite oxidase deficiency and molybdenum cofactor deficiency.12, 13 These pathologies were excluded and we identify here a novel nosological entity.
A whole‐exome analysis showed that patients harbored compound heterozygous mutations in the NIT1 gene. The loss of function of the gene led to the accumulation of dGSH, which was detected in the urine of patients, and probably responsible for the positive urine sulfite test. As recently published,9, 14 dGSH may represent a toxic metabolite, whose accumulation would interfere with the glutathione metabolism and in the long term possibly induce redox damages. Accordingly, an increase in the mitochondrial SOD activity, which is described as an adaptive response to reactive oxygen species‐induced damage, was detected in fibroblasts from the patient. Other pathogenic effect linked to NIT1 deficiency, such as modification of Wnt/beta‐catenin pathways,15 could be involved in patients phenotype.
Overall, we described here a novel autosomal recessive metabolic disorder due to mutations in the NIT1 gene which associates neurological signs, basal ganglia lesions as well as positive urine sulfite test, the latter being easily used to screen for the disease in cohorts of psychiatric patients. Although a characteristic feature of the pathology is the accumulation of the glutathione metabolism intermediate dGSH due to NIT1 loss of function, the pathophysiological mechanisms that could involve a progressive toxicity of dGSH itself and/or increased oxidative stress need to be further investigated to understand neuronal dysfunctions.
Author Contributions
JR: conception and design study, data acquisition, and drafting. LVN: conception and design study, data acquisition, and drafting. CC: conception and design study, data acquisition, and drafting. CG: data acquisition and drafting. JB: data acquisition. IM: data acquisition. JF: conception and design study, data acquisition, and drafting. GB: conception and design study, data acquisition, and drafting.
Conflict of Interest
Nothing to report.
Acknowledgments
We thank all members of the family who participated in this study and Pr J. L. Gueant for his precious help. We also thank the CHUGA NGS platform especially Dr Chatagnon and Mr Vasilev for their technical support.
Funding information
None delcared.
References
- 1. Besson G, Hommel M. Historical aspects of lacunes and the “lacunar controversy”. Adv Neurol 1993;62:1–10. [PubMed] [Google Scholar]
- 2. Marie P. Des foyers lacunaires de désintégration et de différents autres états cavitaires du cerveau. Rev Med 1901;281–298. [Google Scholar]
- 3. Reuling R, Herring A. Cavities in the brain produced by the bacillus aerogenes capsulatus. Bull Johns Hopkins Hosp 1899;62–65. [Google Scholar]
- 4. Ayrignac X, Menjot de Champfleur N, Menjot de Champfleur S, et al. Brain magnetic resonance imaging helps to differentiate atypical multiple sclerosis with cavitary lesions and vanishing white matter disease. Eur J Neurol 2016;23:995–1000. [DOI] [PubMed] [Google Scholar]
- 5. Yavuz H. A review of infantile vanishing white matter disease and a new mutation. Acta Neurol Taiwan 2017;26:167–176. [PubMed] [Google Scholar]
- 6. Lerman‐Sagie T, Leshinsky‐Silver E, Watemberg N, et al. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005;84:127–136. [DOI] [PubMed] [Google Scholar]
- 7. Wong L‐JC. Mitochondrial syndromes with leukoencephalopathies. Semin Neurol 2012;32:55–61. [DOI] [PubMed] [Google Scholar]
- 8. Zhang J, Liu M, Zhang Z, et al. Genotypic spectrum and natural history of cavitating leukoencephalopathies in childhood. Pediatr Neurol 2019;94:38–47. [DOI] [PubMed] [Google Scholar]
- 9. Peracchi A, Veiga‐da‐Cunha M, Kuhara T, et al. Nit1 is a metabolite repair enzyme that hydrolyzes deaminated glutathione. Proc Natl Acad Sci USA 2017;114:E3233–E3242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Jones PM, Bennett MJ. Urine organic acid analysis for inherited metabolic disease using gas chromatography‐mass spectrometry. Methods Mol Biol 2010;603:423–431. [DOI] [PubMed] [Google Scholar]
- 11. Ayrignac X, Carra‐Dalliere C, Menjot de Champfleur N, et al. Adult‐onset genetic leukoencephalopathies: a MRI pattern‐based approach in a comprehensive study of 154 patients. Brain 2015;138(Pt 2):284–292. [DOI] [PubMed] [Google Scholar]
- 12. Scelsa B, Gasperini S, Righini A, et al. Mild phenotype in Molybdenum cofactor deficiency: a new patient and review of the literature. Mol Genet Genomic Med 2019;7:e657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Claerhout H, Witters P, Régal L, et al. Isolated sulfite oxidase deficiency. J Inherit Metab Dis 2018;41:101–108. [DOI] [PubMed] [Google Scholar]
- 14. Niehaus TD, Patterson JA, Alexander DC, et al. The metabolite repair enzyme Nit1 is a dual‐targeted amidase that disposes of damaged glutathione in Arabidopsis. Biochem J 2019;476:683–697. [DOI] [PubMed] [Google Scholar]
- 15. Mittag S, Valenta T, Weiske J, et al. A novel role for the tumour suppressor Nitrilase1 modulating the Wnt/β‐catenin signalling pathway. Cell Discov 2016;2:15039. [DOI] [PMC free article] [PubMed] [Google Scholar]
